European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 2: emerging indications - field cancerization, photorejuvenation and inflammatory/infective dermatoses.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
18
09
2019
accepted:
24
10
2019
pubmed:
6
12
2019
medline:
15
12
2020
entrez:
6
12
2019
Statut:
ppublish
Résumé
In addition to approved indications in non-melanoma skin cancer in immunocompetent patients, topical photodynamic therapy (PDT) has also been studied for its place in the treatment of, as well as its potential to prevent, superficial skin cancers in immune-suppressed patients, although sustained clearance rates are lower than for immune-competent individuals. PDT using a nanoemulsion of ALA in a daylight or conventional PDT protocol has been approved for use in field cancerization, although evidence of the potential of the treatment to prevent new SCC remained limited. High-quality evidence supports a strong recommendation for the use of topical PDT in photorejuvenation as well as for acne, refractory warts, cutaneous leishmaniasis and in onychomycosis, although these indications currently lack approvals for use and protocols remain to be optimized, with more comparative evidence with established therapies required to establish its place in practice. Adverse events across all indications for PDT can be minimized through the use of modified and low-irradiance regimens, with a low risk of contact allergy to photosensitizer prodrugs, and no other significant documented longer-term risks with no current evidence of cumulative toxicity or photocarcinogenic risk. The literature on the pharmacoeconomics for using PDT is also reviewed, although accurate comparisons are difficult to establish in different healthcare settings, comparing hospital/office-based therapies of PDT and surgery with topical ointments, requiring inclusion of number of visits, real-world efficacy as well as considering the value to be placed on cosmetic outcome and patient preference. This guideline, published over two parts, considers all current approved and emerging indications for the use of topical photodynamic therapy in Dermatology prepared by the PDT subgroup of the European Dermatology Forum guidelines committee. It presents consensual expert recommendations reflecting current published evidence.
Substances chimiques
Photosensitizing Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
17-29Informations de copyright
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Morton CA, Szeimies R-M, Sidoroff A, Braathen LR. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications - actinic keratoses, Bowen's disease, basal cell carcinoma. J Eur Acad Dermatol Venereol 2013; 27: 536-544.
Morton CA, Szeimies R-M, Sidoroff A, Braathen LR. European guidelines for topical photodynamic therapy part 2: emerging indications - field cancerization, photorejuvenation and inflammatory/infective dermatoses. J Eur Acad Dermatol Venereol 2013; 27: 672-679.
Morton CA, Szeimies R-M, Sidoroff A et al. European dermatology forum guidelines on topical photodynamic therapy. Eur J Dermatol 2015; 25: 296-311.
Wong TH, Morton CA, Collier N et al. British association of dermatologists and british photodermatology group guidelines for topical photodynamic therapy 2018. Br J Dermatol 2019; 180: 730-739.
http://www.euroderm.org/images/stories/guidelines/guideline_Management_Actinic_Keratoses-update2011.pdf
http://www.euroderm.org/images/stories/guidelines/guideline_Basal_Cell_Carcinoma-update2012%20.pdf
Morton CA, Szeimies R-M, Basset-Seguin N, et al. European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1: treatment delivery and established indications - actinic keratoses, Bowen's disease and basal cell carcinoma. J Eur Acad Dermatol Venereol 2019; https://doi.org/10.1111/jdv.16017.
Hofbauer GF, Anliker M, Arnold A et al. SGDV working group for organ transplant recipients. Swiss clinical practice guidelines for skin cancer in organ transplant recipients. Swiss Med Wkly 2009; 139: 407-415.
Dragieva G, Hafner J, Dummer R et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation 2004; 77: 115-121.
Hasson A, Navarrete-Dechent C, Nicklas C, de la Cruz C. Topical photodynamic therapy with methylaminolevulinate for the treatment of actinic keratosis and reduction of photodamage in organ transplant recipients: a case-series of 16 patients. Indian J Dermatol Venereol Leprol 2012; 78: 448-453.
Dragieva G, Prinz BM, Hafner J et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol 2004; 151: 196-200.
Piaserico S, Belloni Fortina A, Rigotti P et al. Topical photodynamic therapy of actinic keratosis in renal transplant recipients. Transplant Proc 2007; 39: 1847-1850.
Perrett CM, McGregor JM, Warwick J et al. Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol 2007; 156: 320-328.
Togsverd-Bo K, Halldin C, Sandberg C et al. Photodynamic therapy is more effective than imiquimod for actinic keratosis in organ transplant recipients: a randomized intraindividual controlled trial. Br J Dermatol 2018; 178: 903-909.
Schleier P, Hyckel P, Berndt A et al. Photodynamic therapy of virus-associated epithelial tumours of the face in organ transplant recipients. J Cancer Res Clin Oncol 2004; 130: 279-284.
Perrett CM, Tan SK, Cerio R et al. Treatment of basal cell carcinoma with topical methylaminolaevulinate photodynamic therapy in an organ-transplant recipient. Clin Exp Dermatol 2006; 31: 146-147.
Guleng GE, Helsing P. Photodynamic therapy for basal cell carcinomas in organ-transplant recipients. Clin Exp Dermatol 2012; 37: 367-369.
Ulrich C, Jürgensen JS, Degen A et al. Prevention of nonmelanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 2009; 161(Suppl 3): 78-84.
Wulf HC, Pavel S, Stender I, Bakker-Wensveen C. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm Venereol 2006; 86: 25-28.
Wennberg AM, Stenquist B, Stockfleth E et al. Photodynamic therapy with methyl aminolevulinate for prevention of new lesions in transplant recipients: a randomized study. Transplantation 2008; 86: 423-429.
De Graaf Y, Kennedy C, Wolterbeek R et al. Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ transplant recipients: results of a randomized-controlled trial. J Invest Dermatol 2006; 126: 569-574.
Willey A, Mehta S, Lee PK. Reduction in incidence of squamous cell carcinoma in solid organ transplant recipients treated by cyclic photodynamic therapy. Dermatol Surg 2010; 36: 652-658.
Togsverd-Bo K, Lei U, Erlendsson AM et al. Combination of ablative fractional laser and daylight-mediated photodynamic therapy for actinic keratosis in organ transplant recipients - a randomized controlled trial. Br J Dermatol 2015; 172: 467-474.
Slaughter DP, Southwick HW, Smejkal W. “Field cancerization” in oral stratified squamous epithelium. Cancer (Phila.) 1953; 6: 963-968.
Basset-Séguin N, Molès JP, Mils V, Dereure O, Guilhou JJ. TTP53 tumor suppressor gene and skin carcinogenesis. J Invest Dermatol 1994; 103: 102S-106S.
Ren ZP, Pontén F, Nistér M, Pontén J. Two distinct TP53 immunohistochemical patterns in human squamous-cell skin cancer, precursors and normal epidermis. Int J Cancer 1996; 69: 174-179.
South AP, Purdie KJ, Watt SA et al. NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis. J Invest Dermatol 2014; 134: 2630-2638.
Ulrich M, Krueger-Corcoran D, Roewert-Huber J et al. Confocal microscopy for noninvasive monitoring of therapy and detection of subclinical actinic keratoses. Dermatology 2010; 220: 15-24.
Markowitz O, Schwartz M, Feldman E et al. Defining field cancerization of the skin using noninvasive optical coherence tomography imaging to detect and monitor actinic keratosis in ingenol mebutate 0.015%- treated patients. J Clin Aesthet Dermatol 2016; 9: 18-25.
Szeimies RM, Torezan L, Niwa A et al. Clinical, histopathological and immunohistochemical assessment of human skin field cancerization before and after photodynamic therapy. Br J Dermatol 2012; 167: 150-159.
Basset-Seguin N, Baumann Conzett K, Gerritsen MJP et al. Photodynamic therapy for actinic keratoses in organ transplant recipients. J Eur Acad Dermatol Venereol 2013; 27: 57-66.
Apalla Z, Sotiriou E, Chovarda E et al. Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study. Br J Dermatol 2010; 162: 171-175.
Svanberg K, Andersson T, Killander D et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-amino levulinic acid sensitization and laser irradiation. Br J Dermatol 1994; 130: 743-751.
Seyed Jafari S, Cazzaniga S, Hunger RE. Photodynamic therapy as an alternative treatment for mycosis fungoides: a systematic review and meta-analysis. G It Derm Venereol 2018; 153: 827-832.
Edstrom DW, Porwit A, Ros AM. Photodynamic therapy with topical 5-aminolevulinic acid for mycosis fungoides: clinical and histological response. Acta Derm Venereol 2001; 81: 184-188.
Orenstein A, Haik J, Tamir J et al. Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application. Dermatol Surg 2000; 26: 765-769.
Wolf P, Fink-Puches R, Cerroni L, Kerl H. Photodynamic therapy for mycosis fungoides after topical photosensitization with 5-aminolevulinic acid. J Am Acad Dermatol 1994; 31: 678-680.
Ammann R, Hunziker T. Photodynamic therapy for mycosis fungoides after topical photosensitization with 5-aminolevulinic acid. J Am Acad Dermatol 1995; 33: 541.
Leman JA, Dick DC, Morton CA. Topical 5-ALA photodynamic therapy for the treatment of cutaneous T-cell lymphoma. Clin Exp Dermatol 2002; 27: 516-518.
Markham T, Sheahan K, Collins P. Topical 5-aminolaevulinic acid photodynamic therapy for tumour-stage mycosis fungoides. Br J Dermatol 2001; 144: 1262-1263.
Zane C, Venturini M, Sala R, Calzavara Pinton P. Photodynamic therapy with methylaminolevulinate as a valuable treatment option for unilesional cutaneous T-cell lymphoma. Photodermatol Photoimmunol Photomed 2006; 22: 254-258.
Fernandez-Guarino M, Harto A, Perez-Garcia B, Montull C, De Las Heras E, Jaen P. Plaque-phase mycosis fungoides treated with photodynamic therapy: results in 12 patients. Actas Dermosifilogr 2010; 101: 785-791.
Kim ST, Kang DY, Kang JS, Baek JW, Jeon YS, Suh KS. Photodynamic therapy with methyl-aminolaevulinic acid for mycosis fungoides. Acta Derm Venereol 2012; 92: 264-268.
Quéreux G, Brocard A, Saint-Jean M et al. Photodynamic therapy with methyl-aminolevulinic acid for paucilesional mycosis fungoides: A prospective open study and review of the literature. J Am Acad Dermatol 2013; 69: 890-897.
Pileri A, Sgubbi P, Agostinelli C, Infusino SD, Vaccari S, Patrizi A. Photodynamic therapy: an option in mycosis fungoides. Photodiagnosis Photodyn Ther 2017; 20: 107-110.
Calzavara-Pinton PG, Rossi MT, Sala R et al. A retrospective analysis of real-life practice of off-label photodynamic therapy using methyl aminolevulinate (MAL-PDT) in 20 Italian dermatology departments. Part 2: oncologic and infectious indications. J Photochem Photobiol Sci 2013; 12: 158-165.
Sakamoto FH, Lopes JD, Anderson RR. Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice Part 1 Acne: when and why consider photodynamic therapy? J Am Acad Dermatol 2010; 63: 183-193.
Hongcharu W, Taylor CR, Chang Y et al. Topical ALA-photodynamic therapy for the treatment of acne vulgaris. J Invest Dermatol 2000; 115: 183-192.
Pollock B, Turner D, Stringer MR et al. Topical aminolaevulinic acid-photodynamic therapy for the treatment of acne vulgaris: a study of clinical efficacy and mechanism of action. Br J Dermatol 2004; 151: 616-622.
Itoh Y, Ninomiya Y, Tajima S, Ishibashi A. Photodynamic therapy of acne vulgaris with topical delta-aminolaevulinic acid and incoherent light in Japanese patients. J Dermatol 2001; 144: 575-579.
Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using methyl aminolaevulinate: a blinded, randomized, controlled trial. Br J Dermatol 2006; 154: 969-976.
Wiegell S, Wulf HC. Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid versus methyl aminolevulinate. J Am Acad Dermatol 2006; 54: 647-651.
Hörfelt C, Funk J, Frohm-Nilsson M, Wiegleb Edström D, Wennberg AM. Topical methyl aminolaevulinate photodynamic therapy for treatment of facial acne vulgaris: results of a randomized, controlled study. Br J Dermatol 2006; 155: 608-613.
Sakamoto FH, Torezan L, Anderson RR. Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice: part II. Understanding parameters for acne treatment with photodynamic therapy. J Am Acad Dermatol 2010; 63: 195-211.
Pariser DM, Eichenfield LF, Bukhalo M et al. Photodynamic therapy with 80 mg/ml methyl aminolevulinate for severe facial acne vulgaris: a randomized vehicle-controlled study. Br J Dermatol 2016; 174: 770-777.
Barbaric J, Abbott R, Posadzki P et al. Light therapies for acne: abridged Cochrane systematic review including GRADE assessments. Br J Dermatol 2018; 178: 61-75.
Kwon HH, Moon KR, Park SY et al. Daylight photodynamic therapy with 1.5% 3-butenyl 5-aminolevulinate gel as a convenient, effective and safe therapy in acne treatment: a double-blind randomized controlled trial. J Dermatol 2016; 43: 515-521.
Kim TI, Ahn H-J, Kang IH et al. Nonablative fractional laser-assisted daylight photodynamic therapy with topical methyl aminolevulinate for moderate to severe facial acne vulgaris: results of a randomized and comparative study. Photodermatol Photoimmunol Photomed 2017; 33: 253-259.
Nicklas C, Rubio R, Cardenas C, Hasson A. Comparison of efficacy of aminolevulinic acid photodynamic therapy vs. adapalene gel plus oral doxycycline for treatment of moderate acne vulgaris - A simple, blind, randomized, and controlled trial. Photodermatol Photoimmunol Photomed 2019; 35: 3-10.
Xu X, Zheng Y, Zhao Z et al. Efficacy of photodynamic therapy combined with minocycline for treatment of moderate to severe facial acne vulgaris and influence on quality of life. Medicine 2017; 96: 1-6.
Elman M, Lebzelter J. Light therapy in the treatment of acne vulgaris. Dermatol Surg 2004; 30: 139-146.
Yang GL, Zhao M, Wang JM et al. Short-term clinical effects of photodynamic therapy with topical 5-aminolevulinic acid for facial acne conglobate: an open, prospective, parallel-arm trial. Photodermatol Photoimmunol Photomed 2013; 29: 233-238.
Stender IM, Lock-Andersen J, Wulf HC. Recalcitrant hand and foot warts successfully treated with photodynamic therapy with topical 5-aminolaevulinic acid: a pilot study. Clin Exp Dermatol 1999; 24: 154-159.
Stender IM, Na R, Fogh H et al. Photodynamic therapy with 5-aminolaevulinic acid or placebo for recalcitrant foot and hand warts: randomised double-blind trial. Lancet 2000; 355: 963-966.
Fernandez-Guarino M, Harto A, Jaen P. Treatment of recalcitrant viral warts with pulsed dye laser MAL-PDT. J Dermatol Treat 2011; 22: 226-228.
Ohtsuki A, Hasegawa T, Hirasawa Y et al. Photodynamic therapy using light-emitting diodes for the treatment of viral warts. J Dermatol 2009; 36: 525-528.
Schroeter CA, Kaas L, Waterval JJ et al. Successful treatment of periungual warts using photodynamic therapy: a pilot study. JEADV 2007; 21: 1170-1174.
Schroeter CA, Pleunis J, van Nispen tot Pannerden C et al. Photodynamic therapy: new treatment for therapy-resistant plantar warts. Dermatol Surg 2005; 31: 71-75.
Smucler R, Jatsova E. Comparative study of aminolevulic acid photodynamic therapy plus pulsed dye laser versus pulsed dye laser alone in treatment of viral warts. Photomed Laser Surgery 2005; 23: 202-205.
Chong WS, Kang GY. Dramatic clearance of a recalcitrant acral viral wart using methyl aminolevulinate-red light photodynamic therapy. Photodermatol Photoimmunol Photomed 2009; 25: 225-226.
Lu YG, Wu JJ, He Y et al. Efficacy of topical aminolevulinic acid photodynamic therapy for the treatment of verruca planae. Photomed Laser Surgery 2010; 28: 561-563.
Mizuki D, Kaneko T, Hanada K. Successful treatment of topical photodynamic therapy using 5-aminolevulinic acid for plane warts. Br J Dermatol 2003; 149: 1087-1088.
Fathy G, Asaad MK. Daylight photodynamic therapy with methylene blue in plane warts: a randomized double-blind placebo-controlled study. Photodermatol Photoimmunol Photomed 2017; 33: 185-192.
Fehr MK, Hornung R, Degen A et al. Photodynamic therapy of vulvar and vaginal condyloma and intraepithelial neoplasia using topically applied 5-aminolevulinic acid. Lasers Surg Med 2002; 30: 273-279.
Yang YG, Zou XB, Zhao H et al. Photodynamic therapy of condyloma acuminata in pregnant women. Chin Med J 2012; 125: 2925-2928.
Stefanaki IM, Georgiou S, Themelis GC et al. In vivo fluorescence kinetics and photodynamic therapy in condylomata acuminata. Br J Dermatol 2003; 149: 972-976.
Wang XL, Wang HW, Wang HS et al. Topical 5-aminolaevulinic acid-photodynamic therapy for the treatment of urethral condylomata acuminata. Br J Dermatol 2004; 151: 880-885.
Chen K, Chang BZ, Ju M et al. Comparative study of photodynamic therapy vs CO2 laser vaporization in treatment of condylomata acuminata: a randomized clinical trial. Br J Dermatol 2007; 156: 516-520.
Liang J, Lu XN, Tang H et al. Evaluation of photodynamic therapy using topical aminolevulinic acid hydrochloride in the treatment of condylomata acuminata: a comparative, randomized clinical trial. Photodermatol Photoimmunol Photomed 2009; 25: 293-297.
Szeimies RM, Schleyer V, Moll I et al. Adjuvant photodynamic therapy does not prevent recurrence of condylomata acuminata after carbon dioxide laser ablation-A phase III, prospective, randomized, bicentric, double-blind study. Dermatol Surg 2009; 35: 757-764.
Hu Z, Li J, Liu H, Liu L, Jiang L, Zeng K. Treatment of latent or subclinical Genital HPV Infection with 5-aminolevulinic acid-based photodynamic therapy. Photodiagnosis Photodyn Ther 2018; 23: 362-364.
Ao C, Xie J, Wang L et al. 5-aminolevulinic acid photodynamic therapy for anal canal condyloma acuminatum: A series of 19 cases and literature review. Photodiagnosis Photodyn Ther 2018; 23: 230-234.
Asilian A, Davami M. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial. Clin Exp Dermatol 2006; 31: 634-637.
Heras-Mosteiro J, Monge-Maillo B, Pinart M et al. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev 2017; 12: CD005067.
Enk CD, Fritsch C, Jonas F et al. Treatment of cutaneous leishmaniasis with photodynamic therapy. Arch Dermatol 2003; 139: 432-434.
Ghaffarifar F, Jorjani O, Mirshams M, Miranbaygi MH, Hosseini ZK. Photodynamic therapy as a new treatment of cutaneous leishmaniasis. EastMediterr Health J 2006; 12: 902-908.
Sohl S, Kauer F, Paasch U, Simon JC. Photodynamic treatment of cutaneous leishmaniasis. J Dtsch Dermatol Ges 2007; 5: 128-130.
Gardlo K, Hanneken S, Ruzicka T, Neumann NJ. Photodynamic therapy of cutaneous leishmaniasis. A promising new therapeutic modality. Hautarzt 2004; 55: 381-383.
Sainz-Gaspar L, Roson E, Llovo J, Vazquez-Veiga H. Photodynamic therapy in the treatment of cutaneous leishmaniasis. Actas Dermosifiliogr 2019; 110: 249-251.
van der Snoek EM, Robinson DJ, van Hellemond JJ, Neumann HA. A review of photodynamic therapy in cutaneous leishmaniasis. J Eur Acad Dermatol Venereol 2008; 22: 918-922.
Pizinger K, Cetkovska P, Kacerovska D, Kumpova M. Successful treatment of cutaneous leishmaniasis by photodynamic therapy and cryotherapy. Eur J Dermatol 2009; 19: 172-173.
Enk CD, Nasereddin A, Alper R, Dan-Goor M, Jaffe CL, Wulf HC. Cutaneous leishmaniasis responds to daylight-activated photodynamic therapy: proof of concept for a novel self-administered therapeutic modality. Br J Dermatol 2015; 172: 1364-1370.
Evangelou G, Krasagakis K, Giannikaki E, Kruger-Krasagakis S, Tosca A. Successful treatment of cutaneous leishmaniasis with intralesional aminolevulinic acid photodynamic therapy. Photodermatol Photoimmunol Photomed 2011; 27: 254-256.
Akilov OE, Kosaka S, O'Riordan K, Hasan T. Parasiticidal effect of delta-aminolevulinic acid-based photodynamic therapy for cutaneous leishmaniasis is indirect and mediated through the killing of the host cells. Exp Dermatol 2007; 16: 651-660.
Reveiz L, Maia-Elkhoury AN, Nicholls RS, Romero GA, Yadon ZE. Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update. PLoS ONE 2013; 8: e61843.
Karrer S, Kohl E, Feise K et al. Photodynamic therapy for skin rejuvenation: review and summary of the literature - results of a consensus conference of an expert group for aesthetic photodynamic therapy. J Dtsch Dermatol Ges 2013; 11: 137-148.
Ruiz-Rodriguez R, Sanz-Sanchez T, Cordoba S. Photodynamic photorejuvenation. Dermatol Surg 2002; 28: 742-744.
Avram DK, Goldman MP. Effectiveness and safety of ALA-IPL in treating actinic keratoses and photodamage. J Drugs Dermatol 2004; 3(1 Suppl): S36-S39.
Alster TS, Tanzi EL, Welsh EC. Photorejuvenation of facial skin with topical 20% 5-aminolevulinic acid and intense pulsed light treatment: a split-face comparison study. J Drugs Dermatol 2005; 4: 35-38.
Dover JS, Bhatia AC, Stewart B, Arndt KA. Topical 5-aminolevulinic acid combined with intense pulsed light in the treatment of photoaging. Arch Dermatol 2005; 141: 1247-1252.
Gold MH, Bradshaw VL, Boring MM, Bridges TM, Biron JA. Split-face comparison of photodynamic therapy with 5-aminolevulinic acid and intense pulsed light versus intense pulsed light alone for photodamage. Dermatol Surg 2006; 32: 795-801; discussion 801-803.
Bjerring P, Christiansen K, Troilius A, Bekhor P, de Leeuw J. Skin fluorescence controlled photodynamic photorejuvenation (wrinkle reduction). Lasers Surg Med 2009; 41: 327-336.
Kosaka S, Yasumoto M, Akilov OE, Hasan T, Kawana S. Comparative split-face study of 5-aminolevulinic acid photodynamic therapy with intense pulsed light for photorejuvenation of Asian skin. J Dermatol 2010; 37: 1005-1010.
Haddad A, Santos ID, Gragnani A, Ferreira LM. The effects of increasing fluence on the treatment of actinic keratosis and photodamage by photodynamic therapy with 5-aminolevulinic acid and intense pulsed light. Photomed Las Surg 2011; 29: 427-432.
Piccioni A, Fargnoli MC, Schoinas S et al. Efficacy and tolerability of 5-aminolevulinic acid 0.5% liposomal spray and intense pulsed light in wrinkle reduction of photodamaged skin. J Dermatol Treat 2011; 22: 247-253.
Xi Z, Shuxian Y, Zhong L et al. Topical 5-aminolevulinic acid with intense pulsed light versus intense pulsed light for photodamage in Chinese patients. Dermatol Surg 2011; 37: 31-40.
Kohl E, Popp C, Zeman F et al. Photodynamic therapy using intense pulsed light for treating actinic keratoses and photoaged skin of the dorsal hands: a randomized placebo-controlled study. Br J Dermatol 2017; 176: 352-362.
Babilas P, Knobler R, Hummel S et al. Variable pulsed light is less painful than light-emitting diodes for topical photodynamic therapy of actinic keratosis: a prospective randomized controlled trial. Br J Dermatol 2007; 157: 111-117.
Zane C, Capezzera R, Sala R, Venturini M, Calzavara-Pinton P. Clinical and echographic analysis of photodynamic therapy using methylaminolevulinate as sensitizer in the treatment of photodamaged facial skin. Lasers Surg Med 2007; 39: 203-209.
Ruiz-Rodriguez R, Lopez L, Candelas D, Pedraz J. Photorejuvenation using topical 5-methyl aminolevulinate and red light. J Drugs Dermatol 2008; 7: 633-637.
Issa MC, Pineiro-Maceira J, Vieira MT et al. Photorejuvenation with topical methyl aminolevulinate and red light: a randomized, prospective, clinical, histopathologic, and morphometric study. Dermatol Surg 2010; 36: 39-48.
Sanclemente G, Medina L, Villa JF, Barrera LM, Garcia HI. A prospective split-face double-blind randomized placebo-controlled trial to assess the efficacy of methyl aminolevulinate + red-light in patients with facial photodamage. J Eur Acad Dermatol Venereol 2011; 25: 49-58.
Gold MH. The evolving role of aminolevulinic hydrochloride with photodynamic therapy in photoaging. Cutis 2002; 69: 41-46.
Goldman MP, Atkin D, Kincad S. PDT/ALA in the treatment of actinic damage: real world experience. J Las Med Surg 2002; 14: 24.
Touma D, Yaar M, Whitehead S, Konnikov N, Gilchrest BA. A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol 2004; 140: 33-40.
Lane KL, Hovenic W, Ball K, Zachary CB. Daylight PDT: the Southern California experience. Lasers Surg Med 2015; 47: 168-172 A double-blind randomized controlled trial to assess the efficacy of daylight MAL-PDT vs. Placebo and daylight in patients with facial photodamage. Actas Dermosifiliogr 2016; 107: 224-234.
Philipp-Dormston WG, Sanclemente G, Torezan L et al. Daylight photodynamic therapy with MAL cream for large-scale photodamaged skin based on the concept of “actinic field damage”: recommendations of an international expert group. J Eur Acad Dermatol 2016; 30: 8-15.
Torezan L, Chaves Y, Niwa A, Sanches JA, Festa-Neto C, Szeimies RM. A pilot split-face study comparing methyl aminolevulinate-photodynamic therapy (PDT) with microneedling-assisted PDT on actinically damaged skin. Dermatol Surg 2013; 39: 1197-1201.
Ruiz-Rodriguez R, López L, Candelas D, Zelickson B. Enhanced efficacy of photodynamic therapy after fractional resurfacing: fractional photodynamic rejuvenation. J Drugs Dermatol 2007; 6: 818-820.
Wenande E, Phothong W, Bay C, Karmisholt KE, Haedersdal M, Togsverd-Bo K. Efficacy and safety of daylight photodynamic therapy after tailored pretreatment with ablative fractional laser or microdermabrasion: a randomized, side-by-side, single-blind trial in patients with actinic keratosis and large-area field cancerization. Br J Dermatol 2019; 180: 756-764.
Marmur ES, Phelps R, Goldberg DJ. Ultrastructural changes seen after ALA-IPL photorejuvenation: a pilot study. J Cosmet Laser Ther 2005; 7: 21-24.
Orringer JS, Voorhees JJ, Hamilton T et al. Dermal matrix remodeling after nonablative laser therapy. J Am Acad Dermatol 2005; 53: 775-782.
Park MY, Sohn S, Lee ES, Kim YC. Photorejuvenation induced by 5-aminolevulinic acid photodynamic therapy in patients with actinic keratosis: a histologic analysis. J Am Acad Dermatol 2010; 62: 85-95.
Park JY, Jang YH, Kim YS, Sohn S, Kim YC. Ultrastructural changes in photorejuvenation induced by photodynamic therapy in a photoaged mouse model. Eur J Dermatol 2013; 23: 471-477.
Jang YH, Koo GB, Kim JY, Kim YS, Kim YC. Prolonged activation of ERK contributes to the photorejuvenation effect in photodynamic therapy in human dermal fibroblasts. J Invest Dermatol 2013; 133: 2265-2275.
Kim SK, Koo GB, Kim YS, Kim YC. Epithelial-mesenchymal interaction during photodynamic therapy-induced photorejuvenation. Arch Dermatol Res 2016; 308: 493-501.
Wang P, Han J, Wei M et al. Remodeling of dermal collagen in photoaged skin using low-dose 5-aminolevulinic acid photodynamic therapy occurs via the transforming growth factor-ß pathway. J Biophotonics 2018; 11: e201700357.
Kim SK, Oh SJ, Park SY, Kim WJ, Kim YS, Kim YC. Photodynamic therapy inhibits melanogenesis through paracrine effects by keratinocytes and fibroblasts. Pigment Cell Melanoma Res 2018; 31: 277-286.
Zhou BR, Zhang LC, Permatasari F, Liu J, Xu Y, Luo D. ALA-PDT elicits oxidative damage and apoptosis in UVB-induced premature senescence of human skin fibroblasts. Photodiagnosis Photodyn Ther 2016; 14: 47-56.
Bagazgoitia L, Cuevas Santos J, Juarranz A, Jaén P. Photodynamic therapy reduces the histological features of actinic damage and the expression of early oncogenic markers. Br J Dermatol 2011; 165: 144-151.
Watanabe D, Kawamura C, Masuda Y, Akita Y, Tamada Y, Matsumoto Y. Successful treatment of toenail onychomycosis with photodynamic therapy. Arch Dermatol 2008; 144: 19-21.
Piraccini BM, Rech G, Tosti A. Photodynamic therapy of onychomycosis caused by Trichophyton rubrum. J Am Acad Dermatol 2008; 59(5 Suppl): S75-S76.
Figueiredo Souza LW, Souza SV, Botelho AC. Randomized controlled trial comparing photodynamic therapy based on methylene blue dye and fluconazole for toenail onychomycosis. Dermatol Ther 2014; 27: 43-47.
Gilaberte Y, Robres MP, Frias MP, Garcia-Doval I, Rezusta A, Aspiroz C. Methyl aminolevulinate photodynamic therapy for onychomycosis: a multicentre, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol 2017; 31: 347-354.
Morgado LF, Travolo ARF, Muehlmann LA et al. Photodynamic therapy treatment of onychomycosis with aluminium-phthalocyanine chloride nanoemulsions: a proof of concept clinical trial. J Photochem Photobiology B, Biol 2017; 173: 266-270.
Koren A, Salameh F, Sprecher E, Artzi O. Laser-assisted photodynamic therapy or laser-assisted amorolfine lacquer delivery for treatment of toenail onychomycosis: an open-label comparative study. Acta Dermato-Venereologica 2018; 98: 467-468.
Alberdi E, Gomez C. Efficiency of methylene blue-mediated photodynamic therapy vs intense pulsed light in the treatment of onychomycosis in the toenails. Photoderm, Photoimmunol Photomed 2019; 35: 69-77.
Bhatta AK, Keyal U, Wang XL. Photodynamic therapy for onychomycosis: a systematic review. Photodiagnosis Photodyn Ther 2016; 15: 228-235.
Kim YJ, Kim YC. Successful treatment of pityriasis versicolor with 5-aminolevulinic acid photodynamic therapy. Arch Dermatol 2007; 143: 1218-1220.
Lee JW, Kim BJ, Kim MN. Photodynamic therapy: new treatment for recalcitrant Malassezia folliculitis. Lasers Surg Med 2010; 42: 192-196.
Lyon JP, Pedroso e Silva Azevedo Cde M, Moreira LM, de Lima CJ, de Resende MA. Photodynamic antifungal therapy against chromoblastomycosis. Mycopathologia 2011; 172: 293-297.
Hu Y, Huang X, Lu S et al. Photodynamic therapy combined with terbinafine against chromoblastomycosis and the effect of PDT on Fonsecaea monophora in vitro. Mycopathologia 2015; 179: 103-109.
Yang Y, Hu Y, Zhang J et al. A refractory case of chromoblastomycosis due to Fonsecaea monophora with improvement by photodynamic therapy. Med Mycol 2012; 50: 649-653.
Gilaberte Y, Aspiroz C, Alejandre MC et al. Cutaneous sporotrichosis treated with photodynamic therapy: an in vitro and in vivo study. Photomed Laser Surg 2014; 32: 54-57.
Garcia-Malinis AJ, Milagro Beamonte A, Torres Sopena L, Garcia-Callen O, Puertolas-Villacampa P, Gilaberte Y. Cutaneous sporotrichosis treated with methylene blue-daylight photodynamic therapy. J Eur Acad Dermatol Venereol 2018; 32: e90-e91.
Calzavara-Pinton PG, Rossi MT, Aronson E, Sala R; Italian Group For Photodynamic Therapy. A retrospective analysis of real-life practice of off-label photodynamic therapy using methyl aminolevulinate (MAL-PDT) in 20 Italian dermatology departments. Part 1: inflammatory and aesthetic indications. Photochem Photobiol Sci 2013; 12: 148-157.
Schleyer V, Radakovic-Fijan S, Karrer S et al. Disappointing results and low tolerability of photodynamic therapy with topical 5-aminolaevulinic acid in psoriasis. A randomized, double-blind phase I/II study. J Eur Acad Dermatol Venereol 2006; 20: 823-828.
Alster TS, Tanzi EL. Photodynamic therapy with topical aminolevulinic acid and pulsed dye laser irradiation for sebaceous hyperplasia. J Drugs Dermatol 2003; 2: 501-504.
Sakamoto F, Izikson L, Tannous Z, Zurakowski D, Anderson RR. Surgical scar remodelling after photodynamic therapy using aminolaevulinic acid or its methylester: a retrospective, blinded study of patients with field cancerization. Br J Dermatol 2012; 166: 413-416.
Campbell SM, Tyrrell J, Marshall R, Curnow A. Effect of MAL-photodynamic therapy on hypertrophic scarring. Photodiagn Photodyn Ther 2010; 7: 183-188.
Ud-Din S, Thomas G, Morris J et al. Photodynamic therapy: an innovative approach to the treatment of keloid disease evaluated using subjective and objective non-invasive tools. Arch Dermatol Res 2013; 305: 205-214.
Hillemanns P, Untch M, Pröve F, Baumgartner R, Hillemanns M, Korell M. Photodynamic therapy of vulvar lichen sclerosus with 5-aminolevulinic acid. Obstet Gynecol 1999; 93: 71-74.
Romero A, Hernández-Núñez A, Córdoba-Guijarro S, Arias-Palomo D, Borbujo-Martínez J. Treatment of recalcitrant erosive vulvar lichen sclerosus with photodynamic therapy. J Am Acad Dermatol 2007; 57(2 Suppl): S46-S47.
Sotiriou E, Apalla Z, Patsatsi A, Panagiotidou D. Recalcitrant vulvar lichen sclerosis treated with aminolevulinic acid-photodynamic therapy: a report of five cases. J Eur Acad Dermatol Venereol 2008; 22: 1398-1399.
Weisenseel P, Kuznetsov AV, Molin S, Ruzicka T, Berking C, Prinz JC. Photodynamic therapy for granuloma annulare: more than a shot in the dark. Dermatology 2008; 217: 329-332.
Berking C, Hegyi J, Arenberger P, Ruzicka T, Jemec GB. Photodynamic therapy of necrobiosis lipoidica-a multicenter study of 18 patients. Dermatology 2009; 218: 136-139.
Kaae J, Philipsen PA, Wulf HC. Photodynamic therapy of necrobiosis lipoidica using methyl aminolevulinate: a retrospective follow-up study. Photodiagnosis Photodyn Ther 2018; 22: 223-226.
Nayeemuddin FA, Wong M, Yell J, Rhodes LE. Topical photodynamic therapy in disseminated superficial actinic porokeratosis. Clin Exp Dermatol 2002; 27: 703-706.
Curkova AK, Hegyi J, Kozub P, Szep Z, D'Erme AM, Simaljakova M. A case of linear porokeratosis treated with photodynamic therapy with confocal microscopy surveillance. Dermatol Ther 2014; 27: 144-147.
Fustà-Novell S, Podlipnik A, Combalia D et al. Porokeratosis ptychotropica responding to photodynamic therapy: an alternative treatment for a refractory disease. Photodermatol Photoimmunol Photomed 2017; 33: 271-274.
Nardelli AA, Stafinski T, Menon D. Effectiveness of photodynamic therapy for mammary and extra-mammary Paget's disease: a state of the science review. BMC Dermatol 2011; 11: 13.
Gao Y, Zhang XC, Wang WS et al. Efficacy and safety of topical ALA-PDT in the treatment of EMPD. Photodiagnosis Photodyn Ther 2015; 12: 92-97.
Wang HW, Lv T, Zhang LL et al. A prospective pilot study to evaluate combined topical photodynamic therapy and surgery for extramammary paget's disease. Lasers Surg Med 2013; 45: 296-301.
Fontanelli R, Papadia A, Martinelli F et al. Photodynamic therapy with M-ALA as non surgical treatment option in patients with primary extramammary Paget's disease. Gynecol Oncol 2013; 130: 90-94.
Esmann S, Jemec GB. Patients' perceptions of topical treatments of actinic keratosis. J Dermatol Treat 2014; 25: 375-379.
Mikolajewska P, Rømoen OT, Martinsen OG et al. Bioimpedance for pain monitoring during cutaneous photodynamic therapy: preliminary study. Photodiagnosis Photodyn Ther 2011; 8: 307-313.
Zeitouni NC, Paquette AD, Housel JP et al. A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer. Lasers Surg Med 2013; 45: 89-94.
Grapengiesser S, Ericson M, Gudmundsson F, Larkö O, Rosén A, Wennberg AM. Pain caused by photodynamic therapy of skin cancer. Clin Exp Dermatol 2002; 27: 493-497.
Sandberg C, Stenquist B, Rosdahl I et al. Important factors for pain during photodynamic therapy for actinic keratosis. Acta Derm Venereol 2006; 86: 404-408.
Hambly RA, Mansoor N, Quinian C et al. Factors predicting pain and effect of oral analgesia in topical photodynamic therapy. Photodermatol Photoimmunol Photomed 2017; 33: 176-179.
Ibbotson SH, Dawe RS, Morton CA. A survey of photodynamic therapy services in dermatology departments across Scotland. Clin Exp Dermatol 2013; 38: 511-516.
Dixon AJ, Anderson SJ, Dixon MP, Dixon JB. Post procedural pain with photodynamic therapy is more severe than skin surgery. J Plast Reconstr Aesthet Surg 2015; 68: e28-e32.
Szeimies RM. Pain perception during photodynamic therapy: why is daylight PDT with Methyl aminolevulinate almost pain free? G Ital Dermatol Venereol 2018; 153: 793-799.
Paoli J, Halldin C, Ericson MB, Wennberg AM. Nerve blocks provide effective pain relief during topical photodynamic therapy for extensive facial actinic keratoses. Clin Exp Dermatol 2008; 33: 559-564.
Halldin CB, Paoli J, Sandberg C, Gonzalez H, Wennberg AM. Nerve blocks enable adequate pain relief during topical photodynamic therapy of field cancerization on the forehead and scalp. Br J Dermatol 2009; 160: 795-800.
Ericson MB, Sandberg C, Stenquist B et al. Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome. Br J Dermatol 2004; 151: 1204-1212.
Ang JM, Riaz IB, Kamal MU, Paragh G, Zeitouni NC. Photodynamic therapy and pain: a systematic review. Photodiagnosis Photodyn Ther 2017; 19: 308-344.
Ibbotson SH, Wong TH, Morton CA et al. Adverse effects of topical photodynamic therapy: a consensus review and approach to management. Br J Dermatol 2019; 180: 715-729.
Morton CA, Braathen LR. Daylight photodynamic therapy for actinic keratoses. Am J Clin Dermatol 2018; 19: 647-656.
Wilson EC. Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic keratoses: a decision tree model. Pharmacoeconomics 2010; 28: 1055-1064.
Soini EJ, Hallinen T, Sokka AL, Saarinen K. Cost-utility of first-line actinic keratosis treatments in Finland. Adv Ther 2015; 32: 455-476.
Calzavara-Pinton P, Tanova N, Hamon P. Evaluation of the treatment costs and duration of topical treatments for multiple actinic keratosis based on the area of the cancerization field and not on the number of lesions. J Eur Acad Dermatol Venereol 2019; 33: 312-317.
Calzavara-Pinton P, Zane C, Arisi M, Hamon PA, Tanova NT. Evaluation of the costs of topical treatments for actinic keratosis based on lesion response and the affected area. G Ital Dermatol Venereol 2018; 153: 764-775.
Vale SM, Hill D, Feldman SR. Pharmacoeconomic considerations in treating actinic keratosis: an update. Pharmacoeconomics 2017; 35: 177-190.
Neittaanmäki-Perttu N, Grönroos M, Karppinen T, Snellman E, Rissanen P. Photodynamic therapy for actinic keratoses: a randomized prospective non-sponsored cost-effectiveness study of daylight-mediated treatment compared with light-emitting diode treatment. Acta Derm Venereol 2016; 96: 241-244.
Aguilar M, de Troya M, Martin L, Benítez N, González M. A cost analysis of photodynamic therapy with methyl aminolevulinate and imiquimod compared with conventional surgery for the treatment of superficial basal cell carcinoma and Bowen's disease of the lower extremities. J Eur Acad Dermatol Venereol 2010; 24: 1431-1436.
Arits AH, Spoorenberg E, Mosterd K, Nelemans P, Kelleners-Smeets NW, Essers BA. Cost-effectiveness of topical imiquimod and fluorouracil vs. photodynamic therapy for treatment of superficial basal-cell carcinoma. Br J Dermatol 2014; 171: 1501-1507.